Mabpharm Limited (HKG:2181)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
0.3800
-0.0050 (-1.30%)
Jun 18, 2026, 1:47 PM HKT
Market Cap1.59B -14.4%
Revenue (ttm)718.98M +150.2%
Net Income63.58M
EPS0.01
Shares Out 4.12B
PE Ratio34.60
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume188,000
Open0.3200
Previous Close0.3850
Day's Range0.3200 - 0.3800
52-Week Range0.3100 - 0.8800
Beta0.59
AnalystsHold
Price Target1.50 (+294.74%)
Earnings DateAug 28, 2026

About Mabpharm

Mabpharm Limited, a biopharmaceutical company, engages in research, development, production, and commercialization of drugs and biosimilar for cancers and autoimmune diseases in the People’s Republic of China. It offers CMAB007, a recombinant humanized anti-immunoglobulin E monoclonal antibody for treatment of asthma patients; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the first-line treatment of metastatic colorectal cancer; and CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody for the treatment of ulcer... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 389
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2181
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements